Loading company…
Pairui Biotech develops drugs targeting RNA modifications and immune-related diseases.
Pairui Biotech develops drugs targeting RNA modifications using multi-omics experiments and AI-based computational simulations. It also works on molecules for immune and inflammation-related diseases. Founded in 2023, the company is based in Suzhou, China. In February 2025, it raised pre-Series A funding from Suzhou Xincheng Private Equity Fund Management and Oriza Holdings. Founder Jingfang Wang previously worked at Hengrui Medicine and Livzon Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in